COMPARISON OF CHLOROGUANIDE AND MEPHENYTOIN FOR THE IN-VIVO ASSESSMENT OF GENETICALLY-DETERMINED CYP2C19 ACTIVITY IN HUMANS

被引:15
作者
PARTOVIAN, C
JACQZAIGRAIN, E
KEUNDJIAN, A
JAILLON, P
FUNCKBRENTANO, C
机构
[1] UNIV PARIS,HOP ST ANTOINE,CLIN PHARMACOL UNIT,F-75012 PARIS,FRANCE
[2] UNIV PARIS,HOP ROBERT DEBRE,CLIN PHARMACOL UNIT,PARIS,FRANCE
[3] INST MED TROP SERV SANTE ARMEES,MARSEILLE,FRANCE
关键词
D O I
10.1016/0009-9236(95)90241-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: The main objective of this study was to examine the relations between chloroguanide (proguanil) and mephenytoin metabolic ratios to determine whether or not chloroguanide could replace mephenytoin as a probe for the indirect in vivo measurement of CYP2C19 activity. An additional objective was to examine the interactions between chloroguanide, omeprazole, and mephenytoin, which are three substrates of CYP2C19. Methods: Twenty healthy volunteers received 200 mg chloroguanide orally on three separate occasions in an open, randomized-sequence crossover design: once alone, once 2 hours before the oral administration of 100 mg mephenytoin, and once after oral administration for 7 days of 40 mg/day omeprazole. During one additional period, 100 mg mephenytoin was administered orally. The chloroguanide to cycloguanil ratio was determined in plasma 4 hours after drug administration; it was determined in urine collected over 4, 8, and 24 hours. The mephenytoin hydroxylation index was also measured in urine. Results: All subjects were extensive metabolizers of chloroguanide and mephenytoin. We found no correlation between the mephenytoin hydroxylation index and the chloroguanide to cycloguanil ratio in any of the urine samples collected or in plasma. In the presence of chloroguanide, mephenytoin hydroxylation index increased from a baseline value of 1.2 +/- 0.2 to 1.7 +/- 1.0 (p < 0.05). In the presence of omeprazole, the chloroguanide to cycloguanil metabolic ratio in 24-hour urine increased from 2.2 +/- 1.0 to 5.6 +/- 3.2 (p < 0.001). Conclusion: Chloroguanide inhibits the CYP2C19-dependent 4'-hydroxylation of mephenytoin. The bioactivation of chloroguanide to cycloguanil is inhibited by the CYP2C19 substrate omeprazole. However, the chloroguanide to cycloguanil metabolic ratio does not reflect the same array of S-mephenytoin hydroxylase activities found in extensive metabolizers as that shown by the mephenytoin hydroxylation index.
引用
收藏
页码:257 / 263
页数:7
相关论文
共 26 条
[1]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING SECONDARY OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (06) :597-604
[2]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
TASSANEEYAKUL, W ;
TASSANEEYAKUL, W ;
MEYER, UA ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (06) :521-530
[3]   SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS [J].
ANDERSSON, T ;
REGARDH, CG ;
DAHLPUUSTINEN, ML ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :415-416
[4]   IN-VITRO PROGUANIL ACTIVATION TO CYCLOGUANIL BY HUMAN LIVER-MICROSOMES IS MEDIATED BY CYP3A ISOFORMS AS WELL AS BY S-MEPHENYTOIN HYDROXYLASE [J].
BIRKETT, DJ ;
REES, D ;
ANDERSSON, T ;
GONZALEZ, FJ ;
MINERS, JO ;
VERONESE, ME .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (05) :413-420
[5]   ENZYMATIC BASIS OF THE DEBRISOQUINE SPARTEINE-TYPE GENETIC-POLYMORPHISM OF DRUG OXIDATION - CHARACTERIZATION OF BUFURALOL 1'-HYDROXYLATION IN LIVER-MICROSOMES OF INVIVO PHENOTYPED CARRIERS OF THE GENETIC DEFICIENCY [J].
DAYER, P ;
KRONBACH, T ;
EICHELBAUM, M ;
MEYER, UA .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (23) :4145-4152
[6]  
EDSTEIN MD, 1986, J CHROMATOGR, V380, P184, DOI 10.1016/S0378-4347(00)83641-5
[7]  
FUNCKBRENTANO C, 1989, J PHARMACOL EXP THER, V249, P134
[8]   RELATION BETWEEN CHLOROGUANIDE BIOACTIVATION TO CYCLOGUANIL AND THE GENETICALLY-DETERMINED METABOLISM OF MEPHENYTOIN IN HUMANS [J].
FUNCKBRENTANO, C ;
BOSCO, O ;
JACQZAIGRAIN, E ;
KEUNDJIAN, A ;
JAILLON, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (05) :507-512
[9]  
FUNCKBRENTANO C, 1992, J PHARMACOL EXP THER, V263, P780
[10]   EVIDENCE THAT CYP2C19 IS THE MAJOR (S)-MEPHENYTOIN 4'-HYDROXYLASE IN HUMANS [J].
GOLDSTEIN, JA ;
FALETTO, MB ;
ROMKESSPARKS, M ;
SULLIVAN, T ;
KITAREEWAN, S ;
RAUCY, JL ;
LASKER, JM ;
GHANAYEM, BI .
BIOCHEMISTRY, 1994, 33 (07) :1743-1752